Rigetti is a "full stack" quantum computing company that manufactures its own modular and non-modular quantum processing ...

I believe that quantum computing is as exciting as advertised. It holds the potential to accelerate artificial intelligence ...

Johnson & Johnson’s Darzalex Faspro-based quadruplet regimen approved in US for newly diagnosed patients with multiple myeloma who are transplant ineligible: Horsham, Pennsylvan ...

Darzalex Faspro is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase.

FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care?

Ron Brecher from Guelph, Ontario, Canada Barnard 150 is a dark nebula in Cepheus the King that is also known as the Seahorse ...

D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...

The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...

Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and ...

The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...